Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | PGR | P06401 | 2/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.66 |
| ▸ | SHBG | P04278 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606810 | 0.97 | HIF1A (0.67) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL603002 | 0.94 | HIF1A (0.69) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL29064789 | 0.90 | HIF1A (0.68) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL607956 | 0.89 | HIF1A (0.72) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL16020569 | 0.86 | HIF1A (0.78) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL11814284 | 0.86 | HIF1A (0.81) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL8538851 | 0.86 | HIF1A (0.69) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL9789815 | 0.85 | HIF1A (0.66) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL9437393 | 0.84 | HIF1A (0.75) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 | |
| SCHEMBL28131473 | 0.84 | FNTA (0.65) | HIF1ALMNASMN1; SMN2NR3C1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106572970-B | Novel gel for topical administration of non-steroidal anti-inflammatory drugs for relief of musculoskeletal pain and method of making same | 詹姆斯·布兰查德 | 2021-04-06 | — | — | CN | claimed |
| CN-106572970-A | Novel gel for topical administration of non-steroidal anti-inflammatory drugs for relief of musculoskeletal pain and method of making same | 詹姆斯·布兰查德 | 2017-04-19 | — | — | CN | claimed |
| WO-2015191402-A1 | NOVEL GEL FOR TOPICAL DELIVERY OF NSAIDS TO PROVIDE RELIEF OF MUSCULOSKELETAL PAIN AND METHODS FOR ITS PREPARATION | BLANCHARD JAMES (US) | 2015-12-17 | — | — | WO | claimed |
| US-9012402-B1 | Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation | BLANCHARD JAMES (US) | 2015-04-21 | — | — | US | claimed |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | KODIAK SCIENCES INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240189237-A1 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | WATERSHED MEDICAL INC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240156720-A1 | COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-05-16 | — | — | US | disclosed |
| US-20240139133-A1 | TOPICAL NAPROXEN FORMULATIONS AND THEIR USE | SMARTECH TOPICAL, INC. (US) | 2024-05-02 | — | — | US | disclosed |
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4333826-A1 | TOPICAL NAPROXEN FORMULATIONS AND THEIR USE | Smartech Topical, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240050362-A1 | TRANSDERMAL DELIVERY FORMULATIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-02-15 | — | — | US | disclosed |
| US-20030091630-A1 | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data | ASSERTIO THERAPEUTICS, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035041-A1 | GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT | DEPOMED, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003035029-A1 | FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE ORAL DOSAGE FORM USING IN VITRO DISINTEGRATION TEST DATA | DEPOMED, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1239845-A2 | HYDROXIDE-RELEASING AGENTS AS SKIN PERMEATION ENHANCERS | Dermatrends, Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
| US-20020034554-A1 | Dual enhancer composition for topical and transdermal drug delivery | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2002-03-21 | — | — | US | disclosed |
| US-20010051166-A1 | Hydroxide-releasing agents as skin permeation enhancers | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2001-12-13 | — | — | US | disclosed |
| US-20010038861-A1 | Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers | TRS II, LLC | 2001-11-08 | — | — | US | disclosed |
| WO-2001043775-A2 | HYDROXIDE-RELEASING AGENTS AS SKIN PERMEATION ENHANCERS | DERMATRENDS, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, PLAT | HIF1A 1075/4885LMNA 1322/4885SMN1; SMN2 2197/4885 |
| US-20020034554-A1 | Dual enhancer composition for topical and transdermal drug delivery | LIPA, FAAH2, MGLL | HIF1A 1727/4885LMNA 2157/4885SMN1; SMN2 3035/4885 |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, MMP2 | HIF1A 546/4885LMNA 1417/4885SMN1; SMN2 2778/4885 |
| US-20240209076-A1 | USE OF IL-6 ANTIBODIES AND VEGF TRAPS, AND FUSION CONSTRUCTS AND CONJUGATES THEREOF | IL6, FLT4, TEK | HIF1A 584/4885LMNA 3117/4885SMN1; SMN2 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.